Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncertain. We su...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhijuan, Liu, Long, Li, Zhifeng, Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122355/
https://www.ncbi.nlm.nih.gov/pubmed/37085931
http://dx.doi.org/10.1186/s40164-023-00404-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122355/
https://www.ncbi.nlm.nih.gov/pubmed/37085931
http://dx.doi.org/10.1186/s40164-023-00404-3

Ejemplares similares